-
April 2026: This Month in Huntington’s Disease Research
Latest News
-
EuroBuzz News: Day 1
EuroBuzz news: Day 1. Ed and Jeff reporting from the European Huntington’s Disease Network meeting in Stockholm
-
Coming Soon: EuroBuzz 2012
Coming soon from the Euro-HD Network Meeting in Stockholm: EuroBuzz!
-
Lithium with a twist gets second chance for HD
Lithium gets a second chance in HD – with a new chemical delivery method, tested in Huntington’s disease mice
-
High-power brain scans reveal sodium changes in HD
A new brain scanning technique reveals high sodium levels in HD brains. How might this help clinical trials?
-
Mapping the neighborhood: huntingtin's new protein partners
Study of huntingtin protein's 'neighbors' reveals dozens of new drug development targets
-
Does the HD mutation affect children's growth?
A small study suggests kids with the HD mutation but no symptoms have subtle differences in growth. What does it mean
-
'Induced' stem cells make exciting advances
Stem cells from HD patients: becoming important tools for researchers – and now correcting the HD mutation in the lab
-
ASO gene silencing reaches further, lasts longer
Silencing the Huntingtin gene using ASO drugs reaches further, lasts longer and is safe. Human trial soon?
-
Phosphodiesterase inhibitors: new HD drugs entering trials soon
CHDI and Pfizer announce exciting animal work and plans for a human trial with a drug targeting 'phosphodiesterases'.
-
Interview: CHDI's scientific team
HDBuzz interviews the top scientists from CHDI, the largest funder of Huntington's disease research in the world.
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
